{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:51:26Z","timestamp":1792601486453,"version":"4.5.0"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is an autoimmune disease, in which the inflammatory processes involve the skeletal system and there is marked destruction of the bones and the surrounding structures. In this review, we discuss the current concepts of osteoimmunology in RA, which represent the molecular crosstalk between the immune and skeletal systems, resulting in the disruption of bone remodeling. Bone loss in RA can be focal or generalized, leading to secondary osteoporosis. We have summarized the recent studies of bone loss in RA, which focused on the molecular aspects, such as cytokines, autoantibodies, receptor activator of nuclear kappa-\u03b2 ligand (RANKL) and osteoprotegerin (OPG). Apart from the above molecules, the role of aryl hydrocarbon receptor (Ahr), which is a potential key mediator in this process through the generation of the Th17 cells, is discussed. Hence, this review highlights the key insights into molecular mechanisms of bone loss in RA.<\/jats:p>","DOI":"10.3389\/fmed.2022.962969","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T01:52:55Z","timestamp":1660701175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Pathomechanisms of bone loss in rheumatoid arthritis"],"prefix":"10.3389","volume":"9","author":[{"given":"Rajalingham","family":"Sakthiswary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeswaran","family":"Uma Veshaaliini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kok-Yong","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasa Rao","family":"Sirasanagandla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11154-010-9153-1","article-title":"Cellular mechanisms of bone remodeling","volume":"11","author":"Eriksen","year":"2010","journal-title":"Rev Endocr Metab Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1749-6632.2009.05350.x","article-title":"Extracellular regulation of transforming growth factor beta and bone morphogenetic protein signaling in bone","volume":"1192","author":"Nistala","year":"2010","journal-title":"Ann N Y Acad Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1196\/annals.1402.053","article-title":"Multiplicity of BMP signaling in skeletal development","volume":"1116","author":"Wu","year":"2007","journal-title":"Ann N Y Acad Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"20764","DOI":"10.1073\/pnas.0805133106","article-title":"Regulation of bone formation by osteoclasts involves Wnt\/BMP signaling and the chemokine sphingosine-1-phosphate","volume":"105","author":"Pederson","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.2489","article-title":"Suppression of bone formation by osteoclastic expression of semaphorin 4D","volume":"17","author":"Negishi-Koga","year":"2011","journal-title":"Nat Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5152\/eurjrheum.2018.18099","article-title":"Relationship between bone mineral density and anti-citrullinated protein antibody and rheumatoid factor in patients with rheumatoid arthritis","volume":"6","author":"Sargin","year":"2019","journal-title":"Eur J Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/ijms18050905","article-title":"Matrix metalloproteinase gene activation resulting from disordred epigenetic mechanisms in rheumatoid arthritis","volume":"18","author":"Araki","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/rheumatology\/keg037","article-title":"Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis","volume":"42","author":"Green","year":"2003","journal-title":"Rheumatology (Oxford)."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.23812\/21\u201386\u2013L","article-title":"Serum Metalloprotease 3 (MMP-3) biomarker of therapeutic efficacy during treatment of rheumatoid arthritis","volume":"35","author":"Di Spigna","year":"2021","journal-title":"J Biol Regul Homeost Agents."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e22841","DOI":"10.1097\/MD.0000000000022841","article-title":"Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: A protocol for a systematic review and meta-analysis","volume":"99","author":"Sun","year":"2020","journal-title":"Medicine (Baltimore)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"601618","DOI":"10.3389\/fmed.2020.601618","article-title":"Osteoporosis in rheumatoid arthritis: dangerous liaisons","volume":"7","author":"Llorente","year":"2020","journal-title":"Front Med (Lausanne)."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1186\/ar1518","article-title":"The effects of inflammatory arthritis on bone remodeling","volume":"7","author":"Goldring","year":"2005","journal-title":"Arthritis Res Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/blood-2004-01-0041","article-title":"Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment","volume":"104","author":"Rivollier","year":"2004","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.bone.2009.08.050","article-title":"Control of RANKL gene expression","volume":"46","author":"O'Brien","year":"2010","journal-title":"Bone."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1182\/blood-2006-07-037994","article-title":"B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo","volume":"109","author":"Li","year":"2007","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature."},{"key":"B17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/ar3380","article-title":"Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis","volume":"13","author":"Braun","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41232-019-0111-3","article-title":"RANKL biology: bone metabolism, the immune system, and beyond","volume":"40","author":"Ono","year":"2020","journal-title":"Inflamm Regen."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0138189","DOI":"10.1371\/journal.pone.0138189","article-title":"Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone","volume":"10","author":"Xiong","year":"2015","journal-title":"PLoS ONE."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imlet.2009.02.006","article-title":"TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis","volume":"124","author":"Kim","year":"2009","journal-title":"Immunol Lett."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143060","article-title":"Plasma cells promote osteoclastogenesis and periarticular bone loss in autoimmune arthritis","author":"Komatsu","year":"2021","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"706","DOI":"10.14348\/molcells.2017.0225","article-title":"Current understanding of RANK signaling in osteoclast differentiation and maturation","volume":"40","author":"Park","year":"2017","journal-title":"Mol Cells."},{"key":"B23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3389\/fimmu.2014.00511","article-title":"Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond","volume":"5","author":"Walsh","year":"2014","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9","author":"Boyce","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1297-319X(03)00131-3","article-title":"Role for osteoprotegerin in rheumatoid inflammation","volume":"71","author":"Saidenberg-Kermanac'h","year":"2004","journal-title":"Joint Bone Spine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","article-title":"IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17","volume":"47","author":"Hashizume","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0254268","DOI":"10.1371\/journal.pone.0254268","article-title":"RANKL expression in chondrocytes and its promotion by lymphotoxin-\u03b1 in the course of cartilage destruction during rheumatoid arthritis","volume":"16","author":"Takeshita","year":"2021","journal-title":"PLoS ONE."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/rheumatology\/kel045","article-title":"RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis","volume":"45","author":"Pettit","year":"2006","journal-title":"Rheumatology (Oxford)."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1136\/annrheumdis-2014-207137","article-title":"RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation","volume":"75","author":"Danks","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e000365","DOI":"10.1136\/rmdopen-2016-000365","article-title":"Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-\u03ba\u03b2 expression in monocytes from patients with early rheumatoid arthritis","volume":"3","author":"Perp\u00e9tuo","year":"2017","journal-title":"RMD Open."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s10067-017-3570-4","article-title":"Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis","volume":"36","author":"Boman","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"BSR20182356","DOI":"10.1042\/BSR20182356","article-title":"The association between RANK, RANKL and OPG gene polymorphisms and the risk of rheumatoid arthritis: a case-controlled study and meta-analysis","volume":"39","author":"Yang","year":"2019","journal-title":"Biosci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00005-020-00590-6","article-title":"Polymorphisms within the RANK and RANKL encoding genes in patients with rheumatoid arthritis: association with disease progression and effectiveness of the biological treatment","volume":"68","author":"Wieli\u0144ska","year":"2020","journal-title":"Arch Immunol Ther Exp (Warsz)."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e000226","DOI":"10.1136\/rmdopen-2015-000226","article-title":"Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts","volume":"2","author":"Ruyssen-Witrand","year":"2016","journal-title":"RMD Open"},{"key":"B35","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/annrheumdis-2021-219846","article-title":"Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial","volume":"80","author":"So","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","article-title":"Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41981","article-title":"The effect of discontinuing denosumab in patients with rheumatoid arthritis treated with glucocorticoids","volume":"74","author":"Saag","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S0002-9440(10)64417-3","article-title":"Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis","volume":"161","author":"Romas","year":"2002","journal-title":"Am J Pathol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/ard.2009.121764","article-title":"Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis","volume":"69","author":"van Tuyl","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1007\/s00296-011-2175-5","article-title":"Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis","volume":"32","author":"Xu","year":"2012","journal-title":"Rheumatol Int."},{"key":"B41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11914-017-0358-z","article-title":"TNF and bone remodeling","volume":"15","author":"Zhao","year":"2017","journal-title":"Curr Osteoporos Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00198-016-3769-2","article-title":"Biologic therapies and bone loss in rheumatoid arthritis","volume":"28","author":"Zerbini","year":"2017","journal-title":"Osteoporos Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.3390\/jcm10132905","article-title":"Bone metabolism and RANKL\/OPG ratio in rheumatoid arthritis women treated with TNF-alpha inhibitors","volume":"10","author":"Jura-Poltorak","year":"2021","journal-title":"J Clin Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2690402","DOI":"10.1155\/2017\/2690402","article-title":"Effect of tumor necrosis factor inhibitor therapy on osteoclasts precursors in rheumatoid arthritis","volume":"2017","author":"Perpetuo","year":"2017","journal-title":"Biomed Res Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"11535","DOI":"10.1074\/jbc.M607999200","article-title":"Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways","volume":"283","author":"Yoshitake","year":"2008","journal-title":"J Biol Chem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature."},{"key":"B47","doi-asserted-by":"publisher","first-page":"102647","DOI":"10.1016\/j.autrev.2020.102647","article-title":"The role of TH17 cells in multiple sclerosis: therapeutic implications","volume":"19","author":"Moser","year":"2020","journal-title":"Autoimmun Rev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2017-212880","article-title":"In vivo visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption","volume":"77","author":"Matsuura","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1002\/art.39837","article-title":"RANK-independent osteoclast formation and bone erosion in inflammatory arthritis","volume":"68","author":"O'Brien","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity."},{"key":"B52","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.smim.2013.10.001","article-title":"Overview of the interleukin-1 family of ligands and receptors","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0083-6729(06)74015-8","article-title":"Regulation of osteoclast differentiation and function by interleukin-1","volume":"74","author":"Nakamura","year":"2006","journal-title":"Vitam Horm."},{"key":"B54","doi-asserted-by":"publisher","first-page":"782382","DOI":"10.1155\/2015\/782382","article-title":"The role of IL-1\u03b2 in the bone loss during rheumatic diseases","volume":"2015","author":"Ruscitti","year":"2015","journal-title":"Mediators Inflamm."},{"key":"B55","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1210\/er.2007-0038","article-title":"Osteoimmunology: interactions of the bone and immune system","volume":"29","author":"Lorenzo","year":"2008","journal-title":"Endocr Rev."},{"key":"B56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1590\/S0004-27302010000200007","article-title":"Osteoporosis and inflammation","volume":"54","author":"Lacativa","year":"2010","journal-title":"Arq Bras Endocrinol Metabol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrd3669","article-title":"Inflammatory bone loss: pathogenesis and therapeutic intervention","volume":"11","author":"Redlich","year":"2012","journal-title":"Nat Rev Drug Discov."},{"key":"B58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0378-5122(02)00313-4","article-title":"Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphism in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis","volume":"44","author":"Chen","year":"2003","journal-title":"Maturitas."},{"key":"B59","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.molimm.2017.09.003","article-title":"Interleukin 17 regulates SHP-2 and IL-17RA\/STAT-3 dependent Cyr61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis","volume":"91","author":"Ganesan","year":"2017","journal-title":"Mol Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"10397","DOI":"10.3390\/ijms221910397","article-title":"Interleukin-9 facilitates osteoclastogenesis in rheumatoid arthritis","volume":"22","author":"Kar","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13075-020-02315-8","article-title":"Interleukin (IL)-25 suppresses IL-22-induced osteoclastogenesis in rheumatoid arthritis via STAT3 and p38 MAPK\/IkappaBalpha pathway","volume":"22","author":"Min","year":"2020","journal-title":"Arthritis Res Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0195550","DOI":"10.1371\/journal.pone.0195550","article-title":"Clinical management of seronegative and seropositive rheumatoid arthritis: a comparative study","volume":"13","author":"Choi","year":"2018","journal-title":"PLoS ONE."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/jcm10081778","article-title":"Antibodies to citrullinated proteins (ACPA) associate with markers of osteoclast activation and bone destruction in the bone marrow of patients with rheumatoid arthritis","volume":"10","author":"Kurowska","year":"2021","journal-title":"J Clin Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-016-1116-9","article-title":"Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis","volume":"18","author":"Bugatti","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00296-017-3674-9","article-title":"Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients","volume":"37","author":"Llorente","year":"2017","journal-title":"Rheumatol Int."},{"key":"B66","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3892\/etm.2014.2071","article-title":"Wang Y. Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 2647 cells treated with receptor-activated nuclear \u03baB ligand","volume":"9","author":"Lv","year":"2015","journal-title":"Exp Ther Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/jmicro\/52.6.551","article-title":"Cathepsins in the osteoclast","volume":"52","author":"Goto","year":"2003","journal-title":"J Electron Microsc (Tokyo)."},{"key":"B68","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2015-208093","article-title":"Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss","volume":"75","author":"Krishnamurthy","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e0202583","DOI":"10.1371\/journal.pone.0202583","article-title":"Association of high titers of anti-carbamylated protein antibodies with decreased bone mineral density in early arthritis patients","volume":"13","author":"Regueiro","year":"2018","journal-title":"PLoS ONE."},{"key":"B70","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pbiomolbio.2017.12.005","article-title":"The role of aryl hydrocarbon receptor in bone remodeling","volume":"134","author":"Yu","year":"2018","journal-title":"Prog Biophys Mol Biol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00281-013-0392-6","article-title":"Aryl hydrocarbon receptor and experimental autoimmune arthritis","volume":"35","author":"Nguyen","year":"2013","journal-title":"Semin Immunopathol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1073\/pnas.1722124115","article-title":"Shared epitope-aryl hydrocarbon receptor crosstalk underlies the mechanism of gene-environment interaction in autoimmune arthritis","volume":"115","author":"Fu","year":"2018","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B73","doi-asserted-by":"publisher","first-page":"R208","DOI":"10.1186\/ar4046","article-title":"Dendritic cells provide a potential link between smoking and inflammation in rheumatoid arthritis","volume":"14","author":"Kazantseva","year":"2012","journal-title":"Arthritis Res Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12964-014-0048-8","article-title":"AhR and Arnt differentially regulate NF-\u03baB signaling and chemokine responses in human bronchial epithelial cells","volume":"12","author":"\u00d8vrevik","year":"2014","journal-title":"Cell Commun Signal."},{"key":"B75","doi-asserted-by":"publisher","first-page":"17852","DOI":"10.3390\/ijms151017852","article-title":"Intersection of AHR and Wnt signaling in development, health, and disease","volume":"15","author":"Schneider","year":"2014","journal-title":"Int J Mol Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/toxsci\/kfv246","article-title":"Ah receptor activation by dioxin disrupts activin, BMP, and WNT signals during the early differentiation of mouse embryonic stem cells and inhibits cardiomyocyte functions","volume":"149","author":"Wang","year":"2016","journal-title":"Toxicol Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.taap.2015.02.014","article-title":"Combination effects of AHR agonists and Wnt\/\u03b2-catenin modulators in zebrafish embryos: Implications for physiological and toxicological AHR functions","volume":"284","author":"Wincent","year":"2015","journal-title":"Toxicol Appl Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"32104","DOI":"10.18632\/oncotarget.5194","article-title":"A constitutive active MAPK\/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC","volume":"6","author":"Occhi","year":"2015","journal-title":"Oncotarget."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.bone.2009.02.019","article-title":"Dioxins interfere with differentiation of osteoblasts and osteoclasts","volume":"44","author":"Korkalainen","year":"2009","journal-title":"Bone."},{"key":"B80","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.taap.2014.08.025","article-title":"The aryl hydrocarbon receptor suppresses osteoblast proliferation and differentiation through the activation of the ERK signaling pathway","volume":"280","author":"Yu","year":"2014","journal-title":"Toxicol Appl Pharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.yexcr.2016.12.009","article-title":"Aryl hydrocarbon receptor suppresses the osteogenesis of mesenchymal stem cells in collagen-induced arthritic mice through the inhibition of \u03b2-catenin","volume":"350","author":"Tong","year":"2017","journal-title":"Exp Cell Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3390\/cells9102294","article-title":"The role of aryl-hydrocarbon receptor (AhR) in osteoclast differentiation and function","volume":"9","author":"Park","year":"2020","journal-title":"Cells."},{"key":"B83","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.3390\/cells10123498","article-title":"Inhibition of human osteoclast differentiation by kynurenine through the aryl-hydrocarbon receptor pathway","volume":"10","author":"Kim","year":"2021","journal-title":"Cells."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/labinvest.2016.86","article-title":"Sinomenine induces the generation of intestinal Treg cells and attenuates arthritis via activation of aryl hydrocarbon receptor","volume":"96","author":"Tong","year":"2016","journal-title":"Lab Invest."},{"key":"B85","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.biocel.2016.03.014","article-title":"Norisoboldine, an isoquinoline alkaloid, acts as an aryl hydrocarbon receptor ligand to induce intestinal Treg cells and thereby attenuate arthritis","volume":"75","author":"Tong","year":"2016","journal-title":"Int J Biochem Cell Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1093\/rheumatology\/kez655","article-title":"The impact of long-term biologics\/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis","volume":"59","author":"Chen","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"B87","doi-asserted-by":"publisher","first-page":"783030","DOI":"10.3389\/fimmu.2021.783030","article-title":"Different effects of biologics on systemic bone loss protection in rheumatoid arthritis: an interim analysis of a three-year longitudinal cohort study","volume":"12","author":"Chen MH Yu","year":"2021","journal-title":"Front Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e0188454","DOI":"10.1371\/journal.pone.0188454","article-title":"Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS ONE."},{"key":"B89","doi-asserted-by":"publisher","first-page":"799575","DOI":"10.3389\/fimmu.2021.799575","article-title":"The efficacy of denosumab in patients with rheumatoid arthritis: a systematic review and pooled analysis of randomized or matched data","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/ard.2008.104786","article-title":"Interleukin-1 is essential for systemic inflammatory bone loss","volume":"69","author":"Polzer","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10067-019-04771-3","article-title":"Effects of 1-year anti-TNF-\u03b1 therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis","volume":"39","author":"Guly\u00e1s","year":"2020","journal-title":"Clin Rheumatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.11487","article-title":"Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction","volume":"50","author":"Zwerina","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B93","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/art.37797","article-title":"Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis","volume":"65","author":"Binder","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1002\/art.24781","article-title":"Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo","volume":"60","author":"Axmann","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/rheumatology\/kei082","article-title":"Increase in bone mineral densit y of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study","volume":"44","author":"Lange","year":"2005","journal-title":"Rheumatology (Oxford)."},{"key":"B96","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13075-018-1515-1","article-title":"Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX\u00ae: a registry study of RA with osteoporosis\/fracture","volume":"20","author":"Cheng TT Yu","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"B97","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/OARRR.S218448","article-title":"A Swedish register-based, long-term inception cohort study of patients with rheumatoid arthritis - results of clinical relevance","volume":"11","author":"Hafstr\u00f6m","year":"2019","journal-title":"Open Access Rheumatol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/acr.23440","article-title":"Association of high anti-cyclic citrullinated peptide seropositivity and lean mass index with low bone mineral density in rheumatoid arthritis","volume":"70","author":"Wysham","year":"2018","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B99","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/art.41623","article-title":"Association between bone mineral density and autoantibodies in patients with rheumatoid arthritis","volume":"73","author":"Amkreutz","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12325-017-0657-x","article-title":"Association of low bone mineral density with anti-citrullinated protein antibody positivity and disease activity in established rheumatoid arthritis: findings from a US observational cohort","volume":"35","author":"Ahmad","year":"2018","journal-title":"Adv Ther."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.962969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T01:52:59Z","timestamp":1660701179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.962969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":100,"alternative-id":["10.3389\/fmed.2022.962969"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.962969","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"article-number":"962969"}}